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ABSTRACT:
Recent advances in cancer genomics have opened up unlimited potential for 
treating cancer by directly targeting culprit genes. However, novel delivery 
methods are needed in order for this potential to be translated into clinically viable 
treatments for patients. Magnetic nanoparticle technology offers the potential 
to achieve selective and efficient delivery of therapeutic genes by using external 
magnetic fields, and also allows simultaneous imaging to monitor the delivery in 
vivo. Compared to conventional gene delivery strategies, this technique has been 
shown to significantly increase gene delivery to human xenograft tumors models, 
as well as various internal organs (e.g. liver, kidney) and the central nervous 
system. Magnetic nanoparticle technology, therefore, has the potential to turn 
the challenge of gene therapy in vivo into a new frontier for cancer treatment.
TARGETED DELIVERY OF CANCER GENE 
THERAPY
Cancer, at its foundation, can be attributed to one 
or more malfunctioning genes. Gene therapy offers the 
possibility to directly address the root cause of cancer 
through the upregulation or downregulation of target 
genes and, thus, offers a wide range of potential treatment 
strategies for this disease. The most significant challenge 
to effective gene therapy is delivery in vivo [1-3]. Due to 
the presence of nucleases in the bloodstream and immune 
system recognition of foreign nucleic acids, DNA and 
RNA typically have very short half-lives in circulation [4]. 
Approaches that work in vitro are, therefore, hindered by 
the inability of therapeutic genes to reach their intended 
targets in vivo. Certain delivery methods have been shown 
to increase the half-life of gene therapeutics, most notably 
the addition of polyethylene glycol (PEG) to create 
“stealth” delivery methods. PEG is a polymer which, 
when complexed with nucleic acids, prevents proteins and 
nucleic acids from being recognized by the host immune 
system [5]. PEGylation also increases the hydrodynamic 
size of nucleic acids thereby reducing their renal clearance. 
However, even with increases in circulation half-life, 
genes and their carriers still may cause significant side 
effects due to insufficient selectivity in achieving targeted 
delivery with current delivery technologies [6].
Research on targeted gene delivery to cancer tissues 
has focused mostly on conjugation of the therapeutic gene 
payload to antibodies, or other ligands [7]. However, these 
approaches have been limited by challenges in identifying 
antigens or receptors that are specific to tumors. In this 
review article, we will focus on targeted gene delivery 
using magnetic nanoparticles. 
MAGNETIC NANOPARTICLE 
TECHNOLOGY
Magnetic nanoparticles that are used for drug 
delivery purposes are usually crystals between 5-20nm 
in diameter. These crystals are typically iron-based, most 
commonly magnetite or maghemite [8]. Several methods 
for synthesizing these crystals have been developed, the 
most common being co-precipitation of Fe(III) and Fe(II) 
[9]. 
For gene and drug delivery applications, magnetic 
nanoparticles are usually complexed with a delivery 
platform in order to encapsulate the drug or gene, and 
promote cell uptake. Delivery technologies that have been 
used with magnetic nanoparticles include polymeric, viral, 
as well as non-viral platforms. Moreover, several methods 
have been used to form these complexes including 
hydrophobic interactions [10] and electrostatic interactions 
[11]. 
For  in vivo targeting (Figure 1), treatment-
nanoparticle complexes are injected intravenously, Oncotarget 2012; 3:  365-370 366 www.impactjournals.com/oncotarget
intraarterially or intraperitoneally, and an external magnet 
(usually a small rare earth magnet) is attached near the 
target region to create a localized magnetic field. As the 
drug circulates, the applied magnetic field acts on the 
magnetic nanoparticles (and attached drugs) to draw them 
into the surrounding tissue [12]. 
Compared to other delivery methods, magnetic 
nanoparticles have a number of advantages for drug 
delivery because of their demonstrated responsiveness to 
external magnetic fields, relative safety, and versatility. 
Magnetic nanoparticles have been approved for 
clinical use for over a decade as MRI contrast agents 
[13] and, therefore, are one of the better-understood 
nanotechnologies in terms of patient safety. In addition, 
since magnetic nanoparticles are compatible with a wide 
range of existing drug platforms, they can be used to 
effectively deliver a wide variety of therapeutic agents 
[14]. 
TARGETED GENE DELIVERY IN VIVO 
USING MAGNETIC NANOPARTICLES
Magnetism-based  targeted  delivery  was  first 
described in 1978 [15]. However, methods similar to those 
used for drug delivery have significant potential to be used 
for gene therapy delivery. For these applications, though, 
the technology must be adapted to account for the size and 
charge of nucleic acids. 
Of particular interest, magnetically targeted delivery 
offers a potential solution to the delivery issues currently 
hindering the development of effective gene therapies. 
For example, through the use of magnetic nanoparticles 
complexed with gene vectors, therapeutic genes can be 
selectively targeted by an external magnetic field to tumor 
sites in order to increase the concentration of therapeutic 
genes while decreasing the exposure in the rest of the 
body. 
Topical Delivery
Intratumoral injection, or injection near tumor sites, 
has been used to target tumors in clinical trials [16]. 
Magnetofection offers two potential advantages for topical 
delivery to tumors. First, it can increase the cellular uptake 
and retention of payloads at the injection site. Bhattarai 
et al delivered modified adenoviral vectors expressing 
LacZ conjugated with magnetic nanoparticles via direct 
injection into both the jejunum and the trachea [17]. 
Significantly higher levels of beta-galactosidase activity 
were found in the lung and jejunum in magnetic groups, 
indicating enhanced retention and expression under an 
external magnetic field. While this approach may not be 
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Figure 1:  Overview of In Vivo Magnetically Targeted Gene Therapy.Oncotarget 2012; 3:  365-370 367 www.impactjournals.com/oncotarget
applicable as a treatment modality for non-accessible 
tumors, it demonstrates the potential effectiveness of 
magnetofection for enhancing therapeutic gene retention 
with intratumoral injection. 
A second advantage of magnetofection for topical 
delivery is tumor penetration. Current delivery methods 
cannot efficiently deliver therapeutic genes to all regions 
of tumors, especially the hypoxic center, due in part to 
the convoluted nature of the vasculature inside many 
tumors [18]. Moreover, this has been theorized to factor 
into the development of drug resistance. Topical delivery 
by magnetofection has been shown to increase both 
gene accumulation at the target tissue, as well as gene 
penetration into the smaller arteries in the tumor. Krotz 
et al targeted the cremaster muscle after femoral artery 
injection of fluorescently-labeled oligodesoxynucleotides 
and found increased fluorescence in the magnetic group, 
in addition to significant fluorescence in smaller arterioles 
[19]. The increased fluorescence in the smaller arterioles 
showed that magnetic targeting can increase penetration 
into the tissue, suggesting that this approach may enable 
increased penetration of tumor tissue via its blood supply. 
Systemic Delivery
Systemic delivery is the ultimate goal of research on 
novel delivery technologies since it can be used broadly 
in various clinical indications and is convenient to 
administer. Furthermore, human tumor xenograft models 
in mice provide a straightforward way to test targeting 
in vivo, as well as externally-directed magnetofection. 
However, while human tumor xenografts can provide 
valuable insights into the effects of systemic delivery, 
these models are likely to significantly underestimate the 
complexity of targeted delivery in patients. 
Thus far, the most promising application of 
magnetofection as an in vivo cancer therapy has been 
tested using a human tumor xenograft mouse model. 
Using a magnetic nanoparticle–lipid complex delivering 
a luciferase plasmid, Namiki et al found strong luciferase 
activity in animals treated with both nanoparticles and 
an  external  magnet,  but  no  significant  expression  in 
other groups after delivering the same dose of genes 
[10].  This  effect  was  confirmed  in  a  second  trial  in 
tissue homogenates from tumors as evidenced by the 
presence of siRNA directed against the EGF receptor 
in the magnetized groups, and the lack of siRNA in 
the non-magnetized groups. Delivery of EGF receptor 
siRNA was associated with a 50% reduction in tumor 
mass compared to the control group, when targeted by an 
external magnet. This study also showed the differences in 
efficiency between different nanoplex formulations. When 
compared to a previously used magnetic complex, the 
newer formulation showed a 10-fold reduction in siRNA 
accumulation in the non-targeted organs, compared to 
the older formulation, suggesting improved selectivity in 
organ-targeting. This may have been due to the smaller 
size of the newer formulation. Taken together, these 
findings provide strong evidence of a clear therapeutic 
benefit in addition to a proof-of-concept for delivery of a 
reporter gene. 
Monocytes have also been used as gene vectors for 
cancer therapy due to their natural affinity for tumors. In 
this approach, monocytes are first transfected ex vivo and 
then used to deliver therapeutic genes to tumors via the 
bloodstream. This method of gene delivery avoids the 
toxicity issues that arise for the use of non-endogenous 
delivery vehicles. However, previous attempts have been 
hindered by the challenge of targeting adequate numbers 
of cells to tumors [20]. A recent study by Muthana et al 
examined the ability of monocytes grown in the presence 
of magnetic nanoparticles to deliver genes to tumors [21]. 
The authors found 16.9±4.2% of tumor cells expressed 
GFP in the magnetized group, a significant increase over 
the 4.9±3.5% of tumor cells expressing GFP in the non-
magnetized group. No data was shown on whether this led 
to a decrease in monocytes in the liver. While this study 
did not show any therapeutic benefit, since it delivered a 
marker gene, it demonstrated that magnetic nanoparticles 
can be used to improve the utility of cell-based gene 
vectors. 
DELIVERY TO INTERNAL ORGANS 
While  magnetic  gene  delivery  works  best  with 
external organs or tissues, internal organs have been 
effectively targeted using external magnets [22]. Thus 
far, most studies investigating magnetic gene targeting 
of internal organs have used reporter genes. As Namiki 
et al has shown systems that have successfully delivered 
reporter genes can also be used to effectively deliver 
therapeutic genes once they have been optimized [10]. 
Liver
Gene therapy has shown promising results in treating 
hepatocellular carcinoma both in vitro and in vivo. These 
strategies include p53 gene replacement [23] and RNAi-
mediated gene silencing [24]. In both trials, gene therapy 
only worked when genes were directly applied to the 
liver. Direct application allowed researchers to test the 
potential of gene therapy without a systemic delivery 
system. However, due to the invasiveness of intratumoral 
injection, a systemic delivery system may be more broadly 
applicable for clinical applications. 
Magnetically targeted gene delivery has been shown 
to significantly improve systemic delivery efficiency to 
internal organs, and may provide a more viable method 
to delivery these promising gene therapies. Zheng 
et al placed an external magnet near the liver during 
transfection of a luciferase plasmid-magnetic liposome Oncotarget 2012; 3:  365-370 368 www.impactjournals.com/oncotarget
complex, and observed an increase in luciferase activity 
compared to a control group treated without an external 
magnet [11]. In other internal organs analyzed, luciferase 
activity was decreased when a magnet was placed over the 
liver, suggesting that magnetofection not only increases 
transfection at the target site, but also reduces exposure to 
other parts of the body. 
Kidney
Kidneys have been targeted with magnetic gene 
therapy using similar conditions and techniques to the 
liver. Kumar et al secured an external magnet between 
the hind legs of mice to target chitosan-based magnetic 
nanoplexes capable of expressing eGFP to the kidneys and 
found far greater GFP fluorescence than a non-magnetized 
control [25]. However, this study did not address effects on 
tissue near the kidney, which may have also been affected 
by the magnet, or the long-term effects of magnetically 
enhanced delivery. Therefore, while this study showed 
that gene delivery to the kidney could be greatly enhanced 
by magnetic targeting, further studies on the effects on 
neighboring tissue will need to be performed.
DELIVERY TO THE CENTRAL NERVOUS 
SYSTEM 
Delivery to the central nervous system (CNS) faces 
the unique challenge posed by the blood brain barrier, an 
endothelial cell layer that prevents therapeutic genes and 
many other drugs from entering the CNS [26]. Two studies 
conducted on CNS-directed magnetic gene delivery have 
used direct injections to the CNS. Intracranial injection 
allows for gene therapy to reach the brain. However, a less 
invasive method for crossing the blood brain barrier would 
be preferable for clinical applications. 
Spinal Cord
In  the  spinal  cord,  magnetic  nanoparticle/PEI 
complexes have been shown to be targetable following 
intrathecal injection. However, circulation and diffusion 
of the cerebrospinal fluid can reduce transfection at the 
injection site [27]. Using a magnetic nanoplex to deliver 
a pCAG-luc plasmid, Song et al was not only able to 
increase transfection at the injection site in the lumbar 
region, but was also able to specifically target genes in 
the cervical region when the magnet was moved, as 
measured by increased luciferase activity [27]. For spinal 
tumors, this technique offers a unique method for targeting 
various regions of the spine by increasing the effect of a 
therapy at the tumor site and reducing exposure at other 
regions. Moreover, this approach potentially allows for the 
treatment of tumors in the cervical and thoracic regions of 
the spine by means of a lumbar puncture.
Brain
Thus far, no studies have been performed on 
magnetic gene delivery to the developed brain. However, 
adenoviral vectors expressing GFP have been conjugated 
to magnetic nanoparticles and successfully targeted to a 
particular hemisphere of the rat embryonic brain [28]. 
After direct injection into the 3rd ventrical of a rat embryo 
in utero, Sapet et al selectively delivered GFP to one side 
of the embryonic brain after application of an external 
magnet, as detected by fluorescence microscopy [28]. 
While this study showed promise for targeted delivery 
inside the brain, further studies will be necessary to 
determine whether this can approach can be adapted for 
delivery of therapeutic genes to a fully developed adult 
brain. 
FUTURE PERSPECTIVES
Research on magnetically targeted gene therapy, 
while  relatively  new,  has  shown  significant  potential 
to unleash the promise of gene therapy. However, 
many challenges remain, the most significant of which 
is formulation. As Namiki et al showed changes in 
formulation can lead to large changes in selectivity and in 
gene expression [10]. 
The external guiding magnet is another aspect 
that  may  benefit  from  optimization.  Current  methods 
typically use off the shelf magnets, without optimization 
of magnetic field strength or placement. The targeting 
efficiency  of  this  therapy  is  likely  to  be  significantly 
improved by the optimization of these important 
parameters. 
Once these issues are ironed out, the versatility 
inherent to the nanoplex platform holds the potential 
to combine multiple functions into a single treatment. 
Various  research  groups  have  recently  used  the  MRI 
contrast properties of magnetic nanoparticles to monitor 
the biodistribution of these nanoplexes [12]. This ability 
allows for more efficient optimization of the vehicle by 
revealing where these particles are concentrated.
With the addition of targeting components as part 
of the nanoplex, therapy and diagnosis can be combined 
[29]. Targeting ligands such as folate take advantage of 
the higher rate of folate uptake by cancer cells to increase 
selectivity [30]. Moreover, antibodies such as Herceptin 
(which binds to HER2/neu receptor) can be used as well 
[31], allowing for even greater selectivity and, therefore, 
better potential diagnostics with MRI monitoring.
Most importantly, a well-formulated nanoplex may 
improve the use of current therapies. Magnetic targeting, 
as shown by these studies, has the ability to increase the 
efficiency of gene therapy, and may potentially allow for 
the use of promising therapies that are limited by the high 
dosages currently required. Oncotarget 2012; 3:  365-370 369 www.impactjournals.com/oncotarget
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